Stockscreener 앱 받기
3.13
3.26%
0.06
전일 마감가:
$3.07
열려 있는:
$3.08
하루 거래량:
43,443
Relative Volume:
0.16
시가총액:
$130
수익:
-
순이익/손실:
$-31.97M
주가수익비율:
-0.3789
EPS:
-8.2612
순현금흐름:
$-5.66M
1주 성능:
-7.85%
1개월 성능:
+6.73%
6개월 성능:
-10.70%
1년 성능:
-62.15%
1일 변동 폭
$3.03
$3.24
1주일 범위
$3.03
$3.58
52주 변동 폭
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.1005 | 144 | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
547.96 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
809.81 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,051.74 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
142.96 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
218.93 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd 주식(QNTM)의 최신 뉴스
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - Kalkine
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Competitors 2026 - GuruFocus
Quantum BioPharma Ltd (HAM:0K91)Valuation Measures & Financial Statistics - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Valuation - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock News, Headlines & Updates - GuruFocus
Quantum BioPharma (HAM:0K91) EPS (Basic) : €-7.12 (TTM As of Mar. 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) Dividend Yield % : 0.00% (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) OCF Yield % : -22.72 (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - kalkine.ca
QNTM Surges 10.5%: Quantum Biopharma Gains Momentum as It Approaches Key ResistanceIV Crush Alert - Vinanet
Quantum BioPharma Stock Surges as Lucid-MS Progress and Biotech Catalysts Fuel Bullish Momentum - kalkine.ca
Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Fresh Pressure as Biotech Risk and Funding Concerns Weigh on Sentiment - kalkine.ca
Quantum BioPharma reports Q2 results, FDA clears MS trial By Investing.com - Investing.com Nigeria
Quantum BioPharma reports Q2 results, FDA clears MS trial - Investing.com
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - The Manila Times
Quantum BioPharma Reports Q2 2026 Results, Reduces Operating Expenses 53% and Secures FDA Clearance for Lucid-MS Phase 2 Trial - Quiver Quantitative
Quantum BioPharma Reports Q2 2026 Results as FDA Clears Lucid-MS for Phase 2 Multiple Sclerosis Trial - kalkine.ca
Quantum BioPharma (QNTM) doubles liquidity and secures FDA clearance for Lucid-MS Phase 2 - Stock Titan
Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027 - Stock Titan
Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt - Stock Titan
Quantum BioPharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis - NeurologyLive
Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Yahoo Finance
Quantum BioPharma (QNTM) ties August 10 press release into Form F-3 - Stock Titan
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Barchart.com
FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 — QNTM Shares Slide Anyway - kalkine.ca
Quantum BioPharma Ltd. (CN:QNTM) Shares Decline as Clinical Development Risks and Biotech Market Volatility Pressure Investor Sentiment - kalkine.ca
Quantum Biopharma (QNTM) Earnings Date and Reports 2026 - MarketBeat
Quantum Biopharma Ltd (QNTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.20%
자본화:
|
볼륨(24시간):